ClinicalTrials.gg
Not yet recruitingNCT07940205healthy routeUpdated Nov 16, 2026

Machine-learning Algorithm for Prediction of CKD From Retinal Images

An observational study in Chronic Kidney Disease, Hypertension and T2DM (Type 2 Diabetes Mellitus), sponsored by Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI). Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI) · Observational

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

This is a non-interventional study being conducted to validate the performance of a machine learning algorithm for prediction of eGFR from digital retinal images in a target population for future intended use as a populated-based screening tool. Secondary objectives will include prediction of blood pressure (> or ≤ 140/90 mmHg) and presence or absence of T2DM as determined by glycated haemoglobin (HbA1c >6.5%) or on the basis of clinical history. Once validated, the methodology will be deployed for health screening to improve access to healthcare.

02

Conditions studied

  • Chronic Kidney Disease
  • Hypertension
  • T2DM (Type 2 Diabetes Mellitus)
  • eGFR
03

In context

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

This study's planned enrollment of 500 is above the median of 213 across 834 observational studies indexed under Renal Insufficiency, Chronic.

Browse Renal Insufficiency, Chronic studies →

Lead sponsor

Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI) is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population consists of adult patients diagnosed with chronic kidney disease (CKD), hypertension, diabetes mellitus, or without these conditions, attending routine outpatient clinics at Hôpital Universitaire International Cheikh Khalifa Ibn Zaid in Casablanca and Centre Hospitalier Universitaire Hassan II in Fez, Morocco.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  1. Participant must be ≥ 18 years of age, at the time of signing the .
  2. Previously documented ≥ 3months
  3. Any participant with a positive dipstick result for proteinuria of at least trace
  4. Capable of giving signed informed consent as described in Appendix A which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol

Exclusion criteria

Exclusion Criteria:

  • Participants are excluded from the study if any of the following criteria apply:

    1. As judged by the investigator, any evidence of a condition which in the investigator's opinion makes it undesirable for the participant to participate in the study.
    2. Any known eye condition that may preclude clear imaging of the retina for example; cataracts
    3. Individuals with hypertensive emergencies and hyperglycemic or hypoglycemic emergencies
    4. Involvement in the planning and/or conduct of the study (applies to HHA/ AstraZeneca staff and/or staff at the study site).
    5. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • CKD Cases

    350 participants (cases) with diabetes and/or hypertension and/or CKD with previously documented eGFR \< 60 ml/min/1.73m2 ≥3 months

    Diagnostic Test: Machine Learning-Based Algorithm

  • Controls

    150 (controls) with previously documented eGFR ≥ 60 ml/min/1.73m2 ≥ 3 months

    Diagnostic Test: Machine Learning-Based Algorithm

Interventions

  • Diagnostic testMachine Learning-Based Algorithm

    A machine learning-based algorithm analyzes retinal images to assess its ability to detect chronic kidney disease

06

What researchers measure

Primary outcomes

  1. The accuracy of a machine-learning based algorithm to predict high risk CKD from digital retinal images

    To quantify the discrimination of the machine-learning algorithm for identifying the binary target condition of persistent eGFR \<60 mL/min/1.73 m², using standard-of-care serum creatinine as the reference standard and the AUROC with a 95% confidence interval as the primary performance measure

    Time frame: Baseline

Secondary outcomes

  1. Accuracy of the Machine Learning Algorithm for Detection of Hypertension and T2DM

    To quantify the sensitivity, specificity, and discriminative performance of a machine-learning-based algorithm for identifying SBP \>140 mmHg from digital retinal images, using standard-of-care assessment as the reference standard and the AUROC with a 95% confidence interval as the primary performance measure

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Jun 2027, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2026
First posted
Nov 16, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Jun 30, 2027
CompletionEst.
Oct 31, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07940205
Lead sponsor
Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI)
Collaborators
AstraZeneca
Responsible party
Mohamed Khalis (Professor of Epidemiology & Public Health, Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI)) — Principal investigator
First posted
Nov 16, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Mohamed Khalis, Professor
Contact
mkhalis@um6ss.ma
+212 628-245023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion